MRK vs V: Which Is the Better Buy?
Side-by-side comparison of Merck & Co., Inc. and Visa Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Merck & Co., Inc. · Healthcare
$113.87
-12.1% upside to fair value
Grade D
High Quality
VS
Visa Inc. · Financial Services
$327.24
+27.8% upside to fair value
Grade A
High Quality
QuantHub Verdict
V has more upside to fair value
(+27.8%).
V trades at a lower forward P/E
(28.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MRK |
V |
| Current Price |
$113.87 |
$327.24 |
| Fair Value Estimate |
$100.14 |
$418.15 |
| Upside to Fair Value |
-12.1%
|
+27.8%
|
| Market Cap |
$281.2B |
$627.3B |
| Forward P/E |
32.0x
|
28.2x
|
| EV / EBITDA |
17.3x
|
22.6x
|
| Price / Sales |
4.3x
|
14.6x
|
| Price / FCF |
19.9x
|
29.6x
|
| Revenue Growth YoY |
+4.3%
|
+17.1%
|
| Gross Margin |
75.9%
|
81.3%
|
| Operating Margin |
27.6%
|
61.1%
|
| Return on Equity |
17.9%
|
58.9%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.02%
|
3.38%
|
| Analyst Consensus |
Hold
|
Strong Buy
|
Investment Thesis
Merck & Co., Inc. is a leading global healthcare company specializing in pharmaceuticals, vaccines, and animal health products. Its business quality is high, supported by a durable competitive moat anchored in the dominant global position of Keytruda in PD-1/PD-L1 oncology, a strong vaccines portfolio including Gardasil, and scale in R&D and manufacturing. The company benefits from a seasoned lea…
Visa Inc. operates a global payments network that facilitates electronic funds transfers worldwide, primarily through credit and debit cards. The company benefits from a very strong and widening moat driven by its extensive global card network and acceptance infrastructure, supported by a shareholder-friendly capital allocation policy including high buybacks and dividends. Visa's business quality…
Accumulation Zones
| Metric |
MRK |
V |
| Zone Low |
$75.11 |
$313.61 |
| Zone High |
$85.12 |
$355.43 |
| In Buy Zone? |
No
|
Yes
|